Xenova came under pressure to seek a merger in June 2000 when its lead drug XR5000, a topoisomerase inhibitor, proved ineffective in phase II trials in colon cancer. Shares in both companies ...

“He was very excited and said that indenoisoquinoline had the same cytotoxicity profile as some clinically useful topoisomerase I inhibitors,” says Cushman ... Already, results are promising; in one ...